Takeda-backed Ascentage Pharma sets terms for $170 million IPO


Initial public offering hologram, night panoramic view of Bangkok city. The financial center of multinational companies in Asia. The concept of boosting growth through the IPO process. double exposure

Illustrations and 2D photographs

Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK: ASPHF), which is developing treatments for blood cancer, has set terms for a US$170 million initial public offering.

In an SEC filing, Ascentage ( AAPG ) said it plans to offer 7.3 million American Depositary Shares, representing 29.3 million shares of common stock. While the company



Source link

  • Related Posts

    Trump says new 10% tariffs on China could come as early as February 1, repeating November pledge

    Markets were cautiously cautious after Trump took a more lenient approach to China on Monday. That sentiment lasted for a day. Read More Source link

    Here’s what Nvidia says could be the next big trend in artificial intelligence. These 3 stocks could be big winners

    Artificial intelligence (AI) stocks have been some of the best investments made in recent years. But you might be wondering about the next big trend in AI and which stocks…

    Leave a Reply

    Your email address will not be published. Required fields are marked *